Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IDE 397

Next Previous
Drug Profile

IDE 397

Alternative Names: GSK-4362676; IDE-397

Latest Information Update: 21 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator IDEAYA Biosciences
  • Developer Amgen; IDEAYA Biosciences
  • Class Antineoplastics; Small molecules
  • Mechanism of Action MAT2A protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Bladder cancer; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer
  • Phase I/II Solid tumours; Urogenital cancer

Most Recent Events

  • 10 Apr 2025 Phase-I/II clinical trials in Urogenital cancer (Combination therapy) (PO)
  • 13 Feb 2025 IDEAYA Biosciences and Gilead Sciences enters into an additional clinical study collaboration and supply agreement for IDE 397 and sacituzumab-govitecan for Non-small cell lung cancer
  • 13 Feb 2025 IDEAYA Biosciences plans to initiate a clinical trial for Non-small cell lung cancer and Urogenital cancer (Combination therapy) (PO), in the second half of 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top